Back to results
US 2012/0058983 A1Published application
Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
AssigneeBayer Pharma Aktiengesellschaft
InventorsJürgen Klar, Georges VON DEGENFELD, Hans-Georg LERCHEN, Barbara Albrecht-Küpper, Andreas KNORR, Peter SANDNER, Daniel MEIBOM
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension.
Claims7
A compound of formula (I)
- in which
- A is oxygen or sulfur,
- R1 is hydrogen or a group of the formula
- in which
- # is the attachment to the oxygen-atom,
- L1 is linear (C2-C4)-alkanediyl,
- L2 is linear (C1-C3)-alkanediyl,
- R5 and R8 are identical or different and independently selected from the group consisting of hydrogen or a side group of a natural α-amino acid or its homologues or isomers,
- R6 and R9 are independently selected from hydrogen or methyl,
- R7 is hydrogen or (C1-C4)-alkyl, or
- R7 and R5 form together with the atoms which they are attached to a pyrrolidine- or piperidine-ring,
- R10 and R11 are identical or different and are independently selected from hydrogen or (C1-C4)-alkyl,
- wherein (C1-C4)-alkyl may be substituted with one group selected from hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino or di-(C1-C4)-alkylamino, or
- R10 and R8 form together with the atoms which they are attached to a pyrrolidine- or piperidine-ring, and
- R12 is hydrogen or hydroxycarbonyl,
- R2 is hydrogen or a group of the formula —CH2OR1,
- wherein R1 is defined as above,
- R3 is hydrogen, methyl or ethyl,
- R4 is hydrogen, methyl or ethyl, or
- R3 and R4 form together with the nitrogen-atom, which they are bound to, a azetidine-, pyrrolidine- or piperidine-ring,
- wherein the azetidine-, pyrrolidine- or piperidine-ring may be substituted with one or 2 substituents independently selected from the group fluoro, trifluoromethyl, methyl, ethyl, methoxy and ethoxy, and the salts thereof.
18 more elements
(canceled)
Dependencies are inferred from the claim text.